Trial Profile
A Long-Term, Randomized, Double-Blind Study of the Safety, Tolerability and Efficacy of Aclidinum Bromide At Two Dosage Levels When Administered to Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Apr 2017
Price :
$35
*
At a glance
- Drugs Aclidinium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Forest Laboratories
- 31 Jul 2013 Results published in Respiratory Medicine.
- 05 Sep 2012 Tolerability results presented at the 22nd Annual Congress of the European Respiratory Society.
- 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.